This inventor holds 1 USPTO granted patent. Top assignee: Johns Hopkins University. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Katherine Chiappinelli: Innovator in Epigenetic Drug Therapy
Introduction
Katherine Chiappinelli is a prominent inventor based in Baltimore, MD (US). She has made significant contributions to the field of epigenetics, particularly in predicting responses to epigenetic drug therapies. Her work has the potential to transform treatment strategies for patients with varying immune signatures.
Latest Patents
Katherine Chiappinelli holds a patent titled "Predicting response to epigenetic drug therapy." This invention provides methods and compositions that are useful for predicting how patients will respond to epigenetic drug therapies. The invention identifies a unique signature known as the AZA Immune gene set or AIM, which differentiates patients with low and high immune signatures. This differentiation is crucial as it helps determine the most effective treatment options for patients based on their immune response.
Career Highlights
Katherine is affiliated with The Johns Hopkins University, where she conducts her research and develops her innovative ideas. Her work in epigenetics has garnered attention for its potential to improve patient outcomes through personalized medicine.
Collaborations
Katherine collaborates with esteemed colleagues such as Nita Ahuja and Stephen B Baylin. Their combined expertise enhances the research and development of new therapeutic strategies in the field of epigenetics.
Conclusion
Katherine Chiappinelli is a trailblazer in the field of epigenetics, with her innovative patent paving the way for more effective treatment options for patients. Her contributions to science and medicine are invaluable and continue to inspire future research in this critical area.